Shots:
- The US FDA has granted accelerated approval to Trutakna to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression
- Approval was supported by the ongoing global P-III (ORIGIN 3) trial evaluating atacicept (150mg, SC, QW) vs PBO in adults with IgAN, assessing eGFR-based kidney function over 2yrs., with results anticipated in Q3’26
- Trial showed a 46% reduction in proteinuria at 36wks., with a 42% decrease compared to PBO; Pts also experienced a 68% reduction in galactose-deficient IgA1
Ref: Globenewswire | Image: Vera Therapeutics | Press Release
Related News: Vera Therapeutics Reports the US FDA’s BLA Submission for Atacicept to Treat IgA Nephropathy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with usatconnect@pharmashots.com
